## Lisete R Teixeira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1987625/publications.pdf Version: 2024-02-01

		257101	276539
111	2,086	24	41
papers	citations	h-index	g-index
112	112	112	1229
all docs	docs citations	times ranked	citing authors
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Thoracoscopy Talc Poudrage. Chest, 2001, 119, 801-806.	0.4	293
2	Antibiotic Levels in Empyemic Pleural Fluid. Chest, 2000, 117, 1734-1739.	0.4	84
3	Postoperative Pleural Changes after Coronary Revascularization. Chest, 1992, 101, 327-330.	0.4	79
4	Systemic Corticosteroids Decrease the Effectiveness of Talc Pleurodesis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1441-1444.	2.5	72
5	Arterial Blood Gases after Coronary Artery Bypass Surgery. Chest, 1992, 102, 1337-1341.	0.4	69
6	Is Full Postpleurodesis Lung Expansion a Determinant of a Successful Outcome After Talc Pleurodesis?. Chest, 2009, 136, 361-368.	0.4	62
7	Effect of Inhaled Furosemide on the Bronchial Response to Lysine-Aspirin Inhalation in Asthmatic Subjects. Chest, 1992, 102, 408-411.	0.4	60
8	Relationship Between Pleural Effusion and Pericardial Involvement After Myocardial Revascularization. Chest, 1994, 105, 1748-1752.	0.4	51
9	Comparison of Silver Nitrate and Tetracycline as Pleural Sclerosing Agents in Rabbits. Chest, 1995, 108, 1080-1083.	0.4	50
10	Relationship Between Pleural Changes after Myocardial Revascularization and Pulmonary Mechanics. Chest, 1992, 102, 1333-1336.	0.4	48
11	Talc and Silver Nitrate Induce Systemic Inflammatory Effects During the Acute Phase of Experimental Pleurodesis in Rabbits. Chest, 2004, 125, 2268-2277.	0.4	43
12	Silver Nitrate Is Superior to Talc Slurry in Producing Pleurodesis in Rabbits. Chest, 2000, 118, 808-813.	0.4	42
13	Improvements in the 6-Min Walk Test and Spirometry Following Thoracentesis for Symptomatic Pleural Effusions. Chest, 2011, 139, 1424-1429.	0.4	41
14	Evidence that mesothelial cells regulate the acute inflammatory response in talc pleurodesis. European Respiratory Journal, 2006, 28, 929-932.	3.1	38
15	Influence of Antiinflammatory Drugs (Methylprednisolone and Diclofenac Sodium) on Experimental Pleurodesis Induced by Silver Nitrate or Talc. Chest, 2005, 128, 4041-4045.	0.4	36
16	Influence of Atelectasis on Pulmonary Function After Coronary Artery Bypass Grafting. Chest, 1993, 104, 434-437.	0.4	33
17	The Effect of Corticosteroids on Pleurodesis Induced by Doxycycline in Rabbits. Chest, 2002, 121, 216-219.	0.4	33
18	Monoclonal antiâ€vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology, 2009, 14, 1188-1193.	1.3	32

#	Article	IF	CITATIONS
19	Experimental Pleurodesis in Rabbits Induced by Silver Nitrate or Talc. Chest, 2001, 119, 1516-1520.	0.4	31
20	Talc pleurodesis: Evidence of systemic Inflammatory response to small size talc particles. Respiratory Medicine, 2009, 103, 91-97.	1.3	30
21	Predictive models for diagnosis of pleural effusions secondary to tuberculosis or cancer. Respirology, 2009, 14, 1128-1133.	1.3	29
22	Pleurodesis Induced by Talc or Silver Nitrate: Evaluation of Collagen and Elastic Fibers in Pleural Remodeling. Lung, 2006, 184, 105-111.	1.4	28
23	The Utility of Daily Therapeutic Thoracentesis for the Treatment of Early Empyema. Chest, 1999, 116, 1703-1708.	0.4	27
24	Pleural Mesothelial Cells Mediate Inflammatory and Profibrotic Responses in Talc-induced Pleurodesis. Lung, 2007, 185, 343-348.	1.4	27
25	Is Silver Nitrate Pleurodesis for Patients with Malignant Pleural Effusion Feasible and Safe When Performed in an Outpatient Setting?. Annals of Surgical Oncology, 2011, 18, 1145-1150.	0.7	25
26	Management of Malignancy-Associated Pleural Effusion. Treatments in Respiratory Medicine, 2003, 2, 261-273.	1.4	23
27	Intrapleural talc for the treatment of malignant pleural effusions secondary to breast cancer. Cancer, 1995, 75, 2688-2692.	2.0	22
28	Intrapleural Low-Dose Silver Nitrate Elicits More Pleural Inflammation and Less Systemic Inflammation Than Low-Dose Talc. Chest, 2005, 128, 1798-1804.	0.4	22
29	Proinflammatory and Antiinflammatory Cytokine Levels in Complicated and Noncomplicated Parapneumonic Pleural Effusions. Chest, 2012, 141, 183-189.	0.4	22
30	Lung Damage in Experimental Pleurodesis Induced by Silver Nitrate or Talc. Chest, 2002, 122, 2122-2126.	0.4	21
31	Influence of storage time and temperature on pleural fluid adenosine deaminase determination. Respirology, 2006, 11, 488-492.	1.3	21
32	The Effects of Intrapleural Polyclonal Anti-Tumor Necrosis Factor alpha (TNFα) Fab Fragments on Pleurodesis in Rabbits. Lung, 2000, 178, 19-29.	1.4	20
33	Safety and Systemic Consequences of Pleurodesis with Three Different Doses of Silver Nitrate in Patients with Malignant Pleural Effusion. Respiration, 2015, 89, 276-283.	1.2	20
34	Nonhomogeneous Density of CD34 and VCAM-1 Alveolar Capillaries in Major Types of Idiopathic Interstitial Pneumonia. Lung, 2005, 183, 363-373.	1.4	19
35	Transforming growth factor ?-1 as a predictor of fibrosis in tuberculous pleurisy. Respirology, 2007, 12, 660-663.	1.3	19
36	Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer, 2011, 74, 392-395.	0.9	19

#	Article	IF	CITATIONS
37	É possÃvel diferenciar derrames pleurais linfocÃticos secundários a tuberculose ou linfoma através de variáveis clÃnicas e laboratoriais?. Jornal Brasileiro De Pneumologia, 2012, 38, 181-187.	0.4	19
38	Relationship Between Pleural Fluid and Serum Cholesterol Levels. Chest, 2001, 119, 204-210.	0.4	18
39	Reexpansion pulmonary edema. Jornal De Pneumologia, 2003, 29, 101-106.	0.1	17
40	Ultrastructural Acute Features of Active Remodeling After Chemical Pleurodesis Induced by Silver Nitrate or Talc. Lung, 2005, 183, 197-207.	1.4	17
41	Reexpansion pulmonary edema after therapeutic thoracentesis. Clinics, 2010, 65, 1387-1389.	0.6	17
42	Effect of temperature and storage time on cellular analysis of fresh pleural fluid samples. Cytopathology, 2012, 23, 103-107.	0.4	17
43	Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells. Lung, 2015, 193, 831-837.	1.4	17
44	Effectiveness and safety of iodopovidone in an experimental pleurodesis model. Clinics, 2013, 68, 557-562.	0.6	17
45	Doxycycline Pleurodesis in Rabbits. Chest, 1998, 114, 563-568.	0.4	16
46	A new look at old agents for pleurodesis: nitrogen mustard, sodium hydroxide, and silver nitrate. Current Opinion in Pulmonary Medicine, 2000, 6, 281-286.	1.2	16
47	Pulmonary involvement in pleural tuberculosis: How often does it mean disease activity?. Respiratory Medicine, 2011, 105, 1079-1083.	1.3	16
48	Sleep in patients with large pleural effusion: impact of thoracentesis. Sleep and Breathing, 2012, 16, 483-489.	0.9	16
49	Pleural Fluid Adenosine Deaminase (ADA) Predicts Survival in Patients with Malignant Pleural Effusion. Lung, 2016, 194, 681-686.	1.4	15
50	Pulmonary clearance of technetium 99m diethylene triamine penta-acetic acid aerosol in patients with amiodarone pneumonitis. European Journal of Nuclear Medicine and Molecular Imaging, 1990, 17, 334-337.	2.2	14
51	Acute and Chronic Pleural Changes after the Intrapleural Instillation of Mitoxantrone in Rabbits. Lung, 1998, 176, 227-236.	1.4	14
52	Activation of proteinase-activated receptor-2 in mesothelial cells induces pleural inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L734-L740.	1.3	14
53	Serial Observations after High Dose Talc Slurry in the Rabbit Model for Pleurodesis. Lung, 1998, 176, 299-307.	1.4	13
54	Does the Evaluation of Coagulation Factors Contribute to Etiological Diagnosis of Pleural Effusions?. Clinics, 2009, 64, 891-895.	0.6	13

#	Article	IF	CITATIONS
55	Effectiveness and safety of outpatient pleurodesis in patients with recurrent malignant pleural effusion and low performance status. Clinics, 2011, 66, 211-216.	0.6	12
56	Gastropleural fistula from gastric perforation due to renal cell carcinoma after bevacizumab chemotherapy: a case report. Clinics, 2011, 66, 1495-1497.	0.6	12
57	Pleurodesis: A novel experimental model. Respirology, 2007, 12, 500-504.	1.3	11
58	Low doses of silver nitrate induce pleurodesis with a limited systemic response. Respirology, 2009, 14, 885-889.	1.3	11
59	Pleural fluid: Are temperature and storage time critical preanalytical error factors in biochemical analyses?. Clinica Chimica Acta, 2010, 411, 1275-1278.	0.5	11
60	Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions. Lung, 2016, 194, 1021-1027.	1.4	11
61	Experimental pleurodesis induced by antibiotics (macrolides or quinolones). Clinics, 2006, 61, 559-64.	0.6	10
62	Influence of parecoxib (cox-2 inhibitor) in experimental pleurodesis. Respiratory Medicine, 2009, 103, 595-600.	1.3	10
63	Pleurodese nos derrames pleurais malignos: um inquérito entre médicos em paÃses da América do Sul e Central. Jornal Brasileiro De Pneumologia, 2010, 36, 759-767.	0.4	9
64	Selectins and Platelet-Derived Growth Factor (PDGF) in Schistosomiasis-Associated Pulmonary Hypertension. Lung, 2014, 192, 981-986.	1.4	9
65	<i>Corynebacterium parvum versus</i> tetracycline as pleural sclerosing agents in rabbits. European Respiratory Journal, 1995, 8, 2174-2177.	3.1	8
66	Low Concentration Silver Nitrate Pleurodesis in Rabbits: Optimal Concentration for Rapid and Complete Sclerosing Effect. Lung, 2003, 181, 353-359.	1.4	8
67	Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions. Lung Cancer, 2013, 80, 284-288.	0.9	8
68	Distribution of Pleural Injectate. Chest, 1994, 106, 1246-1249.	0.4	7
69	Effectiveness of silver nitrate compared to talc slurry as pleural sclerosing agent in rabbits. Influence of concomitant intrapleural lidocaine. Revista Do Hospital Das Clinicas, 1999, 54, 199-208.	0.5	7
70	Clinical usefulness of Bâ€ŧype natriuretic peptide in the diagnosis of pleural effusions due to heart failure. Respirology, 2011, 16, 495-499.	1.3	7
71	Monoclonal antibodies anti-TGFβ1 and anti-VEGF inhibit the experimental pleurodesis induced by silver nitrate. Growth Factors, 2012, 30, 304-309.	0.5	7
72	Effectiveness of Ethanolamine Oleate as a Pleural Sclerosing Agent in Rabbits. Respiration, 1998, 65, 304-308.	1.2	6

#	Article	IF	CITATIONS
73	Pleural tuberculosis: is radiological evidence of pulmonary-associated disease related to the exacerbation of the inflammatory response?. Clinics, 2012, 67, 1259-1263.	0.6	6
74	Effectiveness of sodium hydroxide as a pleural sclerosing agent in rabbits: Influence of concomitant intrapleural lidocaine. Lung, 1996, 174, 325-32.	1.4	5
75	Effect of Pneumothorax on Pleurodesis Induced With Talc in Rabbits. Chest, 1998, 114, 1143-1146.	0.4	4
76	Talc for Pleurodesis. Chest, 2003, 124, 416.	0.4	4
77	Abrasion Plus Local Fibrin Sealant Instillation Produces Pleurodesis Similar toÂPleurectomy in Rabbits. Chest, 2016, 150, 673-679.	0.4	4
78	Systemic inflammatory acute response in talc pleurodesis using talc of different size particles. Chest, 2004, 126, 726S.	0.4	3
79	Derrame pleural por micobactéria não tuberculosa. Jornal Brasileiro De Pneumologia, 2005, 31, 459-463.	0.4	3
80	PREVALENCE OF GASTROESOPHAGEAL REFLUX IN PATIENTS WITH TRACHEOBRONCHOMALACIA. Chest, 2009, 136, 80S.	0.4	3
81	Respiratory mechanics and pleural remodelling in pleurodesis induced by barium sulphate. Respiratory Physiology and Neurobiology, 2004, 139, 271-280.	0.7	2
82	Cytokines In Pleural Effusion in First 48 Hours After Coronary Artery Bypass Surgery (CABG). Chest, 2004, 126, 896S.	0.4	2
83	Linfoma primário de cavidade pleural em paciente imunocompetente. Jornal Brasileiro De Pneumologia, 2005, 31, 563-566.	0.4	2
84	ACUTE PLEURAL-PULMONARY ALTERATIONS AFTER CABG (CORONARY ARTERY BYPASS GRAFT). Chest, 2005, 128, 361S.	0.4	1
85	Recurrent Post-Traumatic Non-Eosinophilic Pleural Effusion: Report of Three Cases. Clinics, 2008, 63, 414-415.	0.6	1
86	Pleural Pro- and Anti-inflammatory Cytokine Levels Differentiate Noncomplicated From Complicated Parapneumonic Pleural Effusions. Chest, 2010, 138, 339A.	0.4	1
87	Pleurodesis Practice in South and Central American Countries. Chest, 2010, 137, 739-740.	0.4	1
88	Pleurodesis induced by intrapleural injection of silver nitrate or talc in rabbits: can it be used in humans?. Jornal De Pneumologia, 2003, 29, 57-63.	0.1	1
89	Comparing the Systemic Acute Effects of the Pleurodesis Agents Talc and Silver Nitrate. Chest, 2004, 126, 894S.	0.4	0
90	EXPERIMENTAL PLEURODESIS: INTRAPLEURAL INJECTION OF AZYTHROMYCIN, CLARITHROMYCIN OR LEVOFLOXACIN. Chest, 2005, 128, 318S.	0.4	0

#	Article	IF	CITATIONS
91	DOES STORAGE TIME AND TEMPERATURE INTERFERE IN THE ADENOSINE DEAMINASE MEASUREMENT IN PLEURAL EFFUSIONS?. Chest, 2005, 128, 360S.	0.4	0
92	A COST-MINIMIZING DIAGNOSIS MODELS FOR DISCRIMINATION BETWEEN NEOPLASTIC AND TUBERCULOUS PLEURAL EFFUSIONS UTILIZING ROUTINE CLINICAL AND LABORATORY VARIABLES. Chest, 2005, 128, 401S.	0.4	0
93	PLEURAL PDGF EXPRESSION IN MICE EXPOSED TO ASBESTOS FIBERS. Chest, 2006, 130, 276S.	0.4	0
94	DOES THORACENTESIS IMPROVE RESPIRATORY MUSCLE STRENGTH?. Chest, 2007, 132, 620A.	0.4	0
95	ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR DECREASES PLEURAL ADHESIONS IN EXPERIMENTAL PLEURODESIS INDUCED BY TALC. Chest, 2007, 132, 617A.	0.4	0
96	THE IMPACT OF THORACENTESIS ON SUBMAXIMAL EXERCISE CAPACITY: 6-MINUTE WALK TEST. Chest, 2007, 132, 620B.	0.4	0
97	RELATIONSHIP BETWEEN SERUM AND PLEURAL FLUID PRO- AND ANTI-INFLAMMATORY CYTOKINES WITH OUTCOME IN INFECTIOUS PLEURAL EFFUSIONS. Chest, 2007, 132, 462A.	0.4	0
98	INFLUENCE OF THE ANTIINFLAMMATORY COX-2 INHIBITOR (PARECOXIB) ON EXPERIMENTAL PLEURODESIS INDUCED BY TALC OR SILVER NITRATE. Chest, 2007, 132, 617A.	0.4	0
99	Safety and Effectiveness of Three Different Doses of Silver Nitrate for Pleurodesis in Patients With Malignant Pleural Effusion: Preliminary Results. Chest, 2010, 138, 811A.	0.4	0
100	Pleural Elastance And Pressure Curve Morphology Do Not Predict Symptoms During Thoracentesis. , 2011, , .		0
101	Different Concentrations of Lewis Lung Cancer (LLC) Cells in an Experimental Model of Malignant Pleural Disease. Chest, 2014, 146, 429A.	0.4	0
102	Evaluation of Inflammatory Mediators and Apoptosis in Pleural Mesothelial Cells and/or Neoplastic Cells Exposed to Talc Particles. Chest, 2014, 146, 440A.	0.4	0
103	P3.02c-009 Anti-VEGF and Anti-EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model. Journal of Thoracic Oncology, 2017, 12, S1276-S1277.	0.5	0
104	P3.04-034 Differences between Pleurodesis Using Talc and Silver Nitrate at Different Times of Pleural Disease in Mice. Journal of Thoracic Oncology, 2017, 12, S1404.	0.5	0
105	Pleurodese: perspectivas futuras. Jornal De Pneumologia, 2000, 26, 307-312.	0.1	0
106	Cytokines Correlated With the Acute Phases Inflammatory Process in Tuberculous Pleural Effusio. Chest, 2003, 124, 217S.	0.4	0
107	Extracellular Matrix Remodeling in Pleurodesis Induced by Silver Nitrate (SN) or Talc (TL), Collagen and Elastin: 1-Year Evaluatio. Chest, 2003, 124, 220S.	0.4	0
108	CITOKYNES IN BRONCHOALVEOLAR LAVAGE FROM PATIENTS WITH PULMONARY TUBERCULOSIS AND NEGATIVE SPLITUM, Chest. 2005, 128, 4005.	0.4	0

#	Article	IF	CITATIONS
109	PROTEIC PROFILE OF PLEURAL EFFUSIONS SECONDARY TO TUBERCULOSIS AND MALIGNANCY. Chest, 2005, 128, 359S.	0.4	0
110	IMPORTANCE OF INTERFERON-GAMMA IN THE DIAGNOSIS OF TUBERCULOSIS IN PATIENTS WITH HIGH ADENOSINE DEAMINASE LEVELS AND LYMPHOCYTIC PLEURAL FLUIDS. Chest, 2006, 130, 141S.	0.4	0
111	TRANSFORMING GROWTH FACTOR-BETA 1 IN TUBERCULOUS PLEURISY. Chest, 2006, 130, 243S.	0.4	0